Hospital
Northern Inyo Healthcare District
Northern Inyo Healthcare District was paid $3.55M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 0450, Emergency room services — 15% of everything it billed.
33Billing provider infoNORTHERN INYO HEALTHCARE DISTRICT
BISHOP, CA 93514
BISHOP, CA 93514
33aNPI1922198712assigned 10/13/2006
33bProvider typeCritical Access Hospital
28Total paid$3.55M
24GClaims133,404
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#15 of 30
Median peer was paid$3.14M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,873 | $386K | |
| 2019 | 18,392 | $454K | |
| 2020 | 15,721 | $426K | |
| 2021 | 17,219 | $482K | |
| 2022 | 20,708 | $568K | |
| 2023 | 26,536 | $776K | |
| 2024incomplete | 17,955 | $454K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 15% | 8,637 | 7,436 | $515K |
| 80053 | Comprehensive metabolic panel | 7.0% | 11,757 | 10,086 | $248K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.8% | 5,829 | 5,507 | $241K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 2,526 | 2,286 | $220K |
| 87631 | 5.2% | 2,724 | 2,609 | $183K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 845 | 650 | $136K |
| 99199 | Unlisted special service, procedure or report | 3.5% | 2,389 | 2,035 | $126K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.5% | 1,938 | 1,744 | $123K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 2,304 | 1,908 | $113K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 11,735 | 9,729 | $107K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.6% | 3,952 | 3,871 | $92K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 3,552 | 3,076 | $84K |
109 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 1,159 | $77K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 2,140 | $69K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.9% | 1,441 | $67K |
| 83690 | 1.8% | 2,759 | $65K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 1,846 | $63K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.7% | 5,133 | $61K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 951 | $58K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 1,034 | $55K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 1,762 | $53K |
| 80061 | Lipid panel | 1.3% | 3,253 | $47K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 577 | $37K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,678 | $35K |
| 84484 | <1% | 1,976 | $35K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 382 | $33K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,428 | $31K |
| 0250 | <1% | 3,436 | $30K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 706 | $26K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 706 | $26K |
| 81001 | <1% | 4,501 | $25K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,138 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,197 | $25K |
| 97139 | <1% | 893 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,060 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 766 | $19K |
| 85027 | <1% | 2,069 | $17K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 760 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 359 | $16K |
| 86140 | <1% | 1,417 | $16K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 119 | $15K |
| 83880 | <1% | 527 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 178 | $14K |
| Z7502 | <1% | 356 | $13K | |
| 0637 | <1% | 2,574 | $11K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,657 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 523 | $10K |
| 84439 | <1% | 718 | $9K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 112 | $9K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 394 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 893 | $8K |
| 81025 | <1% | 702 | $8K | |
| 85610 | <1% | 1,732 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 173 | $8K |
| 83605 | <1% | 645 | $8K | |
| 97750 | <1% | 124 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,216 | $7K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 232 | $7K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 200 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 183 | $7K |
| 84145 | <1% | 64 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 847 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,109 | $6K |
| 97799 | <1% | 230 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 88 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,969 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 96 | $4K |
| 85652 | <1% | 884 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 125 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 117 | $3K |
| 82570 | <1% | 482 | $3K | |
| 87400 | <1% | 382 | $3K | |
| 86318 | <1% | 116 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 68 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 107 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 58 | $2K |
| 83735 | <1% | 232 | $2K | |
| 86850 | <1% | 157 | $2K | |
| 73030 | <1% | 109 | $2K | |
| 87430 | <1% | 114 | $2K | |
| 0270 | <1% | 256 | $2K | |
| 82043 | <1% | 214 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 27 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 52 | $1K |
| 87081 | <1% | 157 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $1K |
| 85378 | <1% | 175 | $1K | |
| 85730 | <1% | 97 | $1K | |
| 86803 | <1% | 164 | $1K | |
| 86780 | <1% | 80 | $1K | |
| 86901 | <1% | 129 | $982.08 | |
| 82728 | <1% | 81 | $924.60 | |
| 83540 | <1% | 117 | $833.84 | |
| 83550 | <1% | 90 | $731.88 | |
| 84703 | <1% | 73 | $728.46 | |
| 83655 | <1% | 55 | $708.50 | |
| 82607 | <1% | 68 | $626.36 | |
| 87186 | <1% | 68 | $624.24 | |
| 86900 | <1% | 115 | $554.39 | |
| 73630 | <1% | 32 | $549.53 | |
| 73562 | <1% | 29 | $512.27 | |
| 0272 | <1% | 27 | $495.84 | |
| 82962 | <1% | 129 | $434.50 | |
| 84550 | <1% | 86 | $406.22 | |
| Z7610 | <1% | 32 | $405.55 | |
| 81003 | <1% | 144 | $402.37 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 57 | $401.47 |
| 73130 | <1% | 15 | $332.36 | |
| 80299 | <1% | 12 | $318.36 | |
| 73610 | <1% | 13 | $283.04 | |
| 82746 | <1% | 12 | $245.91 | |
| 85018 | <1% | 81 | $222.90 | |
| 87340 | <1% | 26 | $221.00 | |
| 87040 | <1% | 39 | $195.08 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14 | $79.76 |
| 87077 | <1% | 30 | $64.70 | |
| 84156 | <1% | 20 | $58.58 | |
| 0271 | <1% | 12 | $52.00 | |
| J3490 | Unclassified drugs | <1% | 25 | $15.03 |
| 85004 | 0% | 164 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLIS, CHRISTIAN (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Northern Inyo Healthcare District | Bishop, CA | $4.33M |
| Northern Inyo Associates | Bishop, CA | $507K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.